The effect of glucocorticoids on the synthesis and degradation of phosphoenolpyruvate carboxykinase (GTP) (EC 4.1.1.32) in rat liver and kidney in vivo was studied immunochemically. The glucocorticoid analogue triamcinolone (9o-fluoro-11,l,21-dihydroxy16a,17a-isopropylidenedioxypregna-1,4-diene-3,20-dione) increased the synthesis rate of the kidney enzyme in fed rats, but did not further increase the high synthesis rate of this enzyme in starved animals. Both triamcinolone and cortisol decreased the synthesis rate of hepatic phosphoenolpyruvate carboxykinase (GTP) in fed and starved rats, but were without effect on the degradation rate of the enzyme. This effect of triamcinolone in liver was reversed by injection ofdibutyryl cyclic AMP. However, in diabetic animals glucocorticoids increased the synthesis rate ofhepatic phosphoenolpyruvate carboxykinase (GTP). Triamcinolone administration to starved rats in vivo is shown to cause an increase in the portal blood concentrations of insulin and glucose. Since the physiological de-inducer of liver phosphoenolpyruvate carboxykinase (GTP) is insulin, this is the probable cause of the decrease in the synthesis rate of the hepatic enzyme noted when glucocorticoids are administered to non-diabetic animals.
The effect of glucocorticoids on the synthesis and degradation of phosphoenolpyruvate carboxykinase (GTP) (EC 4.1.1.32) in rat liver and kidney in vivo was studied immunochemically. The glucocorticoid analogue triamcinolone (9o-fluoro-11,l,21-dihydroxy16a,17a-isopropylidenedioxypregna-1,4-diene-3,20-dione) increased the synthesis rate of the kidney enzyme in fed rats, but did not further increase the high synthesis rate of this enzyme in starved animals. Both triamcinolone and cortisol decreased the synthesis rate of hepatic phosphoenolpyruvate carboxykinase (GTP) in fed and starved rats, but were without effect on the degradation rate of the enzyme. This effect of triamcinolone in liver was reversed by injection ofdibutyryl cyclic AMP. However, in diabetic animals glucocorticoids increased the synthesis rate ofhepatic phosphoenolpyruvate carboxykinase (GTP) . Triamcinolone administration to starved rats in vivo is shown to cause an increase in the portal blood concentrations of insulin and glucose. Since the physiological de-inducer of liver phosphoenolpyruvate carboxykinase (GTP) is insulin, this is the probable cause of the decrease in the synthesis rate of the hepatic enzyme noted when glucocorticoids are administered to non-diabetic animals.
There is confusion in the literature over the effect of glucocorticoid administration on hepatic phosphoenolpyruvate carboxykinase (GTP) (EC 4.1.1.32) activity in the rat. Several papers (Shrago et al., 1963; Foster et al., 1966; Wicks et al., 1969; Huttner et al., 1974; Krone et al., 1974) report that single or multiple injections of cortisone, cortisol or triamcinolone § into intact fed or adrenalectomized fed rats cause an increase in hepatic enzyme activity. Similarly in Reuber H35 hepatoma cells in culture, physiological concentrations of glucocorticoids increase phosphoenolpyruvate carboxykinase activity (Barnett & Wicks, 1971; Wicks et al., 1974) . Longshaw et al. (1972) show that, whereas a single injection of triamcinolone abolishes the normal rhythm of the liver enzyme, multiple injections increase enzyme activity. However, Reshef et al. (1969) find that triamcinolone has no effect in fed animals. Further, in starved rats, glucocorticoids decrease (Ray et al., 1964; Foster et al., 1966; Reshefet al., 1969) whereas in diabetic animals they increase (Reshef et al., 1970; Exton et al., 1973) hepatic phosphoenolpyruvate carboxykinase activity. Such conflicting results apparently argue against a direct role Wicks et al., 1974) for the glucocorticoids in the regulation of this enzyme.
One possible interpretation is that the effect of glucocorticoids on hepatic phosphoenolpyruvate carboxykinase is secondary to their primary role in regulating other metabolic systems. This is partially supported by the observations that, although the activity of renal phosphoenolpyruvate carboxykinase is markedly elevated by a single injection of triamcinolone (Longshaw & Pogson, 1972; , enzyme activity from adipose tissue is decreased by glucocorticoids (Reshef et al., 1969 (Reshef et al., , 1970 Reshef & Hanson, 1972 Hopgood et al. (1973) .
Animals
Male Wistar rats (150-170g) were fed on standard laboratory chow and maintained on a cycle of alternating 12h periods of darkness and light with the light period starting at 07:00h. To minimize diurnal variation the experiments were started between 07:00and 09:00h except for the 18h point in Fig. 4in which case the animals were injected with triamcinolone at 15:00h and killed 18h later. Diabetes was induced by the subcutaneous injection into starved rats of 7.5mg of alloxan per lOOg body weight. The animals were used 5-7 days later when marked glucosuria had developed; when they were killed they had blood glucose values in excess of 400mg/lOOml.
Immunoprecipitation ofphosphoenolpyruvate carboxykinase Kidney and liver cytosolic phosphoenolpyruvate carboxykinases are immunologically identical (Longshaw & Pogson, 1972) and the same procedure was used for the immunoprecipitation ofthe enzyme from both tissues. In experiments measuring synthesis of the enzyme, rats were injected with 200,uCi of [4,5-3H] leucine intraperitoneally and killed 30min later. The livers and kidneys were removed and homogenized in 0.25M-sucrose and a cytosol fraction was prepared by centrifugation at 105000g for 40min. The activity of phosphoenolpyruvate carboxykinase was determined for each cytosol fraction by a modification of the method of Chang & Lane (1966) . One unit ofenzyme activity catalyses the fixation of I pmol ofNaH'4C03/ min at 37°C. The radioactivity incorporated into phosphoenolpyruvate carboxykinase isolated as an antigen-antibody complex and into total cytosol protein was determined as described previously Hopgood et al., 1973; Tilghman et al., 1974) . The pulse-labelling period of 30min used in the synthesis experiments is less than 10 % ofthe reported half-life ofphosphoenolpyruvate carboxykinase (Shrago et al., 1963; Reshef et al., 1970; Treadow & Khairallah, 1972; Hopgood et al., 1973; . Thus any error arising from protein turnover involved in measuring enzyme synthesis will be negligible. Synthesis rates for phosphoenolpyruvate carboxykinase are expressed both as the radioactivity incorporated into the enzyme/30min per mg of tissue and as the percentage incorporation relative to cytosol protein. The latter method allows for variability in the amount of label injected. Also, when synthesis is expressed as a relative rate, any changes in the precursor leucine pool will not influence the results provided that total cytosol proteins and phosphoenolpyruvate carboxykinase are synthesized from the same pool of amino acids.
In the degradation experiment, starved rats were injected with 200,uCi of [4,5-3H]leucine followed by a chase of 12.5,umol of unlabelled L-leucine 1 h later. The animals were killed 1, 7 and 18h after the injection ofradioactive leucine, and the extent of labelling of the enzyme and cytosol protein was determined as indicated above. The degradation rate of phosphoenolpyruvate carboxykinase is measured as the rate of isotope loss after the enzyme pool has been labelled with radioactive L-leucine. Data are expressed as the relative amount present compared with radioactivity in total cytosol proteins. The rate of degradation of phosphoenolpyruvate carboxykinase will therefore be underestimated because of the turnover of all proteins. However, provided that the turnover of the enzyme is rapid compared with that of the average for protein, the error will not be large.
Insulin andglucose determinations Serum insulin was assayed by the method of Soeldner & Slone (1965) and blood glucose by the method of Hill & Kessler (1961) .
Results
Hepatic phosphoenolpyruvate carboxykinase is responsive to induction by injected dibutyryl cyclic AMP (Reshef & Hanson, 1972; Hanson et al., 1973; Tilghman et al., 1974) as shown by an increased activity and rate of enzyme synthesis 2h after injection (Table 1) . Triamcinolone, however, markedly decreased the relative synthesis rate of hepatic phosphoenolpyruvate carboxykinase 7h after injection into fed rats (Table 1) . This change was not due to a large alteration in the rate of cytosol protein synthesis, for although triamcinolone slightly depressed the incorporation of leucine into liver cytosol proteins, the effect of the glucocorticoid on phosphoenolpyruvate carboxykinase was greater 1975 Table 1 . Effect ofdibutyryl cyclic AMP, triamcinolone and cortisol on hepatic phosphoenolpyruvate carboxykinase synthesis in fed rats Triamcinolone was injected intraperitoneally at a dose of 5mg/1OOg body weight at time zero. Cortisol was given intraperitoneallyat 2.5mg/lOOg at 0 and 3.5h and dibutyryl cyclic AMP, 2.5mg/animal, at 5 and 6h. All animals were injected with pH]leucine at 6.5h and killed at 7h. Phosphoenolpyruvate carboxykinase was assayed and the synthesis rate determined as described in the Experimental section. The data are presented as the means ± S.E.M. of the numbers of observations in parentheses.
Radioactivity incorporated (c.p.m./mg of liver) Treatment None (10) Dibutyryl cyclic AMP (6) Triamcinolone (6) Cortisol ( (Table 1 ). The renal enzyme was not affected by dibutyryl cyclic AMP and was increased in activity by triamcinolone owing to a 2-3-fold increase in its relative rate of synthesis (Table 2 ). This effect of the glucocorticoid was expected on the basis ofpublished observations (Longshaw & Pogson, 1972; . There was little change in the synthesis rate of renal cytosol proteins indicating that the effect of triamcinolone was specific to phosphoenolpyruvate carboxykinase.
There are a number of possible explanations for the decreased rate of hepatic phosphoenolpyruvate carboxykinase synthesis found in fed rats (Table 1) . Triamcinolone is not a naturally occurring glucocorticoid and is relatively long-lived in vivo (Florin et al., 1961) . Therefore its effect on the hepatic enzyme might not be shared by other glucocorticoids. However, cortisol phosphate (Table 1) gave quantitatively similar results. It increased the relative synthesis rate of the kidney enzyme and decreased the relative synthesis rate of liver phosphoenolpyruvate carboxykinase. Again these changes in the relative rate of enzyme synthesis were not due to gross changes in total cytosol protein synthesis Vol. 150 (Table 1) . A dose-response curve (Fig. 1 ) also indicates that 0.1 mg of triamcinolone per lOOg body weight effectively lowers the relative synthesis rate of hepatic phosphoenolpyruvate carboxykinase 7h after injection into fed rats. This dose-response curve is similar to that reported by us for the effect of triamcinolone on hepatic enzyme activity in adrenalectomized starved rats (Reshef et al., 1969) and suggests that the amount of hormone administered in Table 1 was not excessive. Foster et al. (1966) reported that, after a single injection of cortisol or triamcinolone into fed intact or adrenalectomized rats, hepatic phosphoenolpyruvate carboxykinase activity increased for 4h then decreased to the control value by 8h. Assuming no increase in the degradation rate, these data might reflect an initial increase followed, between 4 and 8 h, by a marked decrease in the synthesis rate for the enzyme. To test this possible interpretation of our results, we followed the time-course of the effect of triamcinolone on the liver and kidney enzymes in fed rats (Fig. 2) . In both tissues, triamcinolone had no effect on the relative synthesis rate of phosphoenolpyruvate carboxykinase over the first 3h. Thereafter Triamcinolone (mg) Hanson et al., 1973; Tilghman et al., 1974; Wicks et al., 1974) . It seemed possible that glucocorticoids decrease the synthesis rate of hepatic phosphoenolpyruvate carboxykinase either by antagonizing cyclic AMP within the hepatocyte or by increasing the concentrations and/or effectiveness of insulin. Since the concentration of cyclic AMP in the rat liver is increased by starvation and diabetes (Jefferson et al., 1968; Exton et al., 1971 Exton et al., , 1973 Park & Exton, 1972) , the effect of triamcinolone on the synthesis rate of the enzyme was investigated under these conditions.
Triamcinolone was found to be as effective in lowering the synthesis rate of hepatic phosphoenolpyruvate carboxykinase in starved ( Table 3 . Effect oftriamcinolone on hepatic phosphoenolpyruvate carboxykinase synthesis in starved rats In Expts. A and C, rats starved overnight were injected intraperitoneally with triamcinolone (5mg/1OOg) at time zero and, in Expt. C, with dibutyryl cyclic AMP (2.5mg/animal) at 5 and 6h. The animals were given [3H]leucine at 6.5h and the activity and synthesis rate of phosphoenolpyruvate carboxykinase determined as described in the Experimental section. In Expt. B, fed rats were injected with triamcinolone (5mg/1OOg) and were then starved for 24h before receiving cyclic AMP prevents the decrease in hepatic phosphoenolpyruvate carboxykinase synthesis normally seen when diabetic rats are treated with insulin (Tilghman et al., 1974) .
Since insulin and cyclic AMP are major regulators of the liver enzyme and insulin is known to decrease hepatic cyclic AMP concentrations (Park & Exton, 1972; Park et al., 1972) , it is possible that insulin Vol. 150 release in response to glucocorticoids might be a key factor in the marked decrease in the rate of hepatic phosphoenolpyruvate carboxykinase synthesis. In partial support of this hypothesis we find ( (0) were injected intraperitoneally with 5mg of triamcinolone/lOOg body weight (0) at time zero. At the time-points shown, the rats were anaesthetized and approx. 4ml of blood was withdrawn from the portal vein. Each point is the mean+S.E.M. of four observations for serum insulin (a) and blood glucose (b). observations of changes in enzyme activity (Ray et al., 1964; Foster et al., 1966; Reshef et al., 1969 Reshef et al., , 1970 Exton et al., 1973) . Direct effects of a single hormone are most readily distinguished from interactions with other hormones in an isolated system. We have shown Tilghman et al., 1975) that the relative synthesis rate of phosphoenolpyruvate carboxykinase in Reuber H35 cells is increased by dexamethasone and dibutyryl cyclic AMP, although the effect of the glucocorticoid is small compared with the cyclic nucleotide. Thus, in the absence of insulin, either in vivo or in Reuber H35 cells in culture, glucocorticoids are able to increase the relative synthesis rate of phosphoenolpyruvate carboxykinase.
However, in normal animals glucocorticoids are known to elicit insulin release (Cambell et al., 1966; Malaisse et al., 1967; Owen & Cahill, 1973; Curry & Bennett, 1973; Altszuler et al., 1974) . Therefore, in non-diabetic animals, if triamcinolone is affecting hepatic phosphoenolpyruvate carboxykinase via insulin, an increase in portal blood insulin should occur at the same time or before the decrease in relative synthesis rate of the enzyme (Fig. 2) . Also, there should be a concomitant increase in blood glucose concentration since this is a necessary requirement for insulin release. The data in Fig. 3 clearly demonstrate that a single injection of triamcinolone increases the portal blood concentrations of insulin and glucose in starved rats. Further, these changes precede the decrease in the synthesis rate of hepatic phosphoenolpyruvate carboxykinase (Fig. 2) .
Although triamcinolone decreases the synthesis rate of the liver enzyme, it does not always lower the activity of the enzyme within 7h (Tables 1 and 3 ). Thus the steroid (or insulin) might be decreasing both the rates of synthesis and degradation of the enzyme. Fig. 4 shows that triamcinolone has no effect on the relative degradation rate of hepatic phosphoenolpyruvate carboxykinase. The labelling in cytosol proteins remained approximately constant. The calculated half-lives for the radioactive enzyme under these conditions were 6.7 and 6.9h respectively for the control and steroid-treated animals, which agree with the value of approx. 6h reported in the literature (Shrago et al., 1963; Reshef et al., 1970; Treadow & Khairallah, 1972; Hopgood et al., 1973) . Since the synthesis rate ofthe enzyme is not depressed 1975 until approx. 4h after the administration of triamcinolone (Fig. 2) and the degradation rate is unaffected, the activity as measured over 7h may not be correspondingly decreased. Over a longer timecourse, triamcinolone significantly decreased the activity of the liver enzyme (Fig. 4) presumably because of the marked decrease in synthesis.
Discussion
A number of investigators have reported that the injection of glucocorticoids into intact rats causes an elevation in hepatic phosphoenolpyruvate carboxykinase activity (Shrago et al., 1963; Foster et a!., 1966; Wicks et al., 1969; Longshaw & Pogson, 1972; Huttner et al., 1974; Krone et al., 1974) . In our own studies (Reshef et al., 1969 (Reshef et al., , 1970 Hepatic phosphoenolpyruvate carboxykinase activity is increased in starvation and diabetes (Shrago et al., 1963; Foster et al., 1966) conditions associated with an increased hepatic cyclic AMP concentration (Jefferson et al., 1968; Exton et al., 1971 Exton et al., , 1973 Park & Exton, 1972) , and by administration of glucagon or dibutyryl cylic AMP (Shrago et al., 1963; Wicks etal., 1969; Reshef & Hanson, 1972) . Such changes (Tables 1, 3 and 5) are due to an increase in the synthesis rate for the enzyme Hopgood et al., 1973; Hanson et al., 1973; Tilghman et al., 1974) . Re-feeding or insulin treatment of diabetic rats produces a decrease in enzyme activity (Shrago et al., 1963; Foster et al., 1966 ) through a rapid fall (half-time 40min) in synthesis rate Tilghman et al., 1974) and in both cases this is blocked by dibutyryl cyclic AMP (Tilghman et al., 1974) . Insulin also antagonizes the stimulatory effect ofthe cyclicnucleotide on phosphoenolpyruvate carboxykinase activity and synthesis rate in Reuber H35 cells in culture (Barnett & Wicks, 1971; Wicks et al., 1974; Vol. 150 a!., Tilghman et al., 1975) . Thus a high concentration of insulin effectively counteracts the stimulatory effect ofcyclic AMP on enzyme synthesis.
The analogy between these experiments with cyclic AMP and insulin and those reported here leads us to conclude that insulin is mediating the glucocorticoid effect on the synthesis rate of hepatic phosphoenolpyruvate carboxykinase in normal animals. In support of this we have shown that triamcinolone evokes insulin release in vivo, even in starved animals ( Fig. 3) and that this precedes the decrease in the synthesis rate of hepatic phosphoenolpyruvate carboxykinase (Fig. 2) . In keeping with the antagonistic actions ofcyclic AMP and insulin on the enzyme, subsequent injection of dibutyryl cyclic AMP prevents this depressive effect of triamcinolone on enzyme synthesis (Table 3) . Further circumstantial evidence is provided by the opposite response to glucocorticoids of hepatic phosphoenolpyruvate carboxykinase in diabetic animals (Table 5 ) and by the response of the renal enzyme in fed animals. As shown in Table 2 , the synthesis rate of renal phosphoenolpyruvate carboxykinase is markedly increased by the administration of glucocorticoids. The kidney enzyme is not directly affected by insulin, being responsive instead to insulin-induced changes in the acid-base status of the animal (Longshaw & Pogson, 1972; Kamm et al., 1974) . Therefore an increased pancreatic output of insulin after glucocorticoid injection would not result in a decreased rate of enzyme synthesis but rather an induction due to the steroid. It is probable that much of the confusion in the literature over the effects of glucocorticoids on hepatic phosphoenolpyruvate carboxykinase in vivo revolves around the use of diabetic or non-diabetic animals as well as the efficacy with which different glucocorticoids are able, either directly or indirectly, to evoke insulin release.
Glucocorticoids increase the rate of hepatic gluconeogenesis both by altering the supply of glucose precursors and by changing the rate of glucose synthesis from these substrates (Russell, 1955; Renold et al., 1956; Ray et al., 1964; Dunn et al., 1969) . In diabetic animals this is accompanied by an increase in the activity (Reshef et al., 1970; Exton et al., 1973) and synthesis rate (Table 5) of phosphoenolpyruvate carboxykinase. In normal animals, however, before these changes in the enzyme occur, the increase in blood glucose and insulin promoted by triamcinolone (Fig. 3) will produce a decrease in gluconeogenesis (Park & Exton, 1972; Park et al., 1972) and a decrease in the synthesis rate of the enzyme (Fig. 2) . Similarly, the ability of glucocorticoids to induce hepatic glycogen deposition largely depends on insulin secretion (Kreutner & Goldberg, 1967; Nichols & Goldberg, 1972; Exton et al., 1973 (Banett & Wicks, 1971; Wicks et al., 1974) and the synthesis rate of the enzyme, a situation analogous to their effect in the diabetic animal in vivo (Table 5 ). Wicks and coworkers Wicks et al., 1974) have suggested that glucocorticoids induce the enzyme at the level of transcription whereas cyclic AMP acts at some post-transcriptional step. Evidence also points to a transcriptional effect of glucocorticoids in the stimulation of renal phosphoenolpyruvate carboxykinase (Iynedjian et al., 1975) . However, definitive proof of this mechanism awaits the isolation and quantification of specific mRNA coding for the enzyme. If glucocorticoids are major regulators of hepatic phosphoenolpyruvate carboxykinase, then enzyme activity should be decreased in adrenalectomized animals. This does not occur. Enzyme activity is the same as in intact animals and the normal starved response is not impaired (Shrago et al., 1963; Ray et al., 1964; Foster et al., 1966; Reshef et al., 1969) . This suggests that the glucocorticoids might not be required to maintain hepatic phosphoenolpyruvatecarboxykinase at normal values and that they may play some secondary role in the regulation of the hepatic enzyme. The mechanism whereby glucocorticoids alter the rate of gluconeogenesis in mammalian liver is also not clear. Currently they are thought to interact with cyclic AMP in a so-called 'permissive' way, that is, they augment the action of cyclic AMP. Thus the stimulation of gluconeogenesis by glucagon, adrenaline or cyclic AMP is decreased in the perfused livers of adrenalectomized rats, even though these compounds cause an increase in the intracellular content of cyclic AMP. Rates of glucose synthesis can be restored to normal, however, by treatment with glucocorticoids either administered to the animal in vivo or included in the perfusion medium (Friedmann et al., 1967; Park & Exton, 1972; Exton et al., 1973) . In agreement with these findings, the response of phosphoenolpyruvate carboxykinase to dibutyryl cyclic AMP is decreased in the livers of adrenalectomized rats (Wicks et al., 1974; Krone et al., 1974) . It is possible, therefore, that the 'permissive' effect of glucocorticoids on gluconeogenesis, as well as the stimulation of hepatic phosphoenolpyruvate carboxykinase synthesis which occurs in vivo in the absence of insulin and in Reuber H35 cells, reflect some general modulation of cyclic AMP action by the glucocorticoids.
